Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + interferon
- Development stage
- Unknown
- Lead developer
- Bayer Pharmaceuticals
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
Sorafenib + interferon is a combination therapy consisting of the small molecule multikinase inhibitor sorafenib and an immunomodulatory cytokine, typically interferon alpha (either alpha-2a or alpha-2b). Sorafenib inhibits tumor cell proliferation by blocking the RAF/MEK/ERK pathway and reduces angiogenesis by inhibiting vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) signaling. Interferon-alpha exerts antitumor effects primarily through antiangiogenic activity and immune regulation. This combination has been investigated in clinical trials for advanced renal cell carcinoma (RCC) and melanoma, showing preliminary antitumor activity with manageable toxicity profiles[1][2][5]. The combination is not approved as a standard regimen but has demonstrated efficacy in phase I/II studies.
- Brand names
- Nexavar (for sorafenib)
- Other names
- sorafenib plus interferon-alphasorafenib + IFN-alpha
02
Targets
RAF1 (c-Raf-1 (Y340D/Y341D))PDGFRB (Platelet-derived growth factor receptor beta)IFNAR (Immune system modulation via type I interferon receptor)RUVBL2 (RuvB-like AAA ATPase 2)BRAF (B-Raf proto-oncogene, serine/threonine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MAPK14 (p38 mitogen-activated protein kinase alpha)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on sorafenib + interferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + interferon.